Airiver Medical Wins FDA Breakthrough Device Status for Pulmonary Drug Coated Balloon to Treat Central Airway Stenosis

Airiver Medical has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for its pulmonary drug-coated balloon (DCB) designed to treat central airway stenosis, a condition that causes narrowing of the airway and can significantly impair breathing.

The FDA’s Breakthrough Device program is intended to accelerate the development and regulatory review of innovative medical technologies that have the potential to provide more effective treatment options for serious or life-threatening conditions.

A New Approach to Treating Airway Narrowing

Central airway stenosis can result from prolonged intubation, tracheostomy procedures, infections, lung transplantation, or airway stenting. Current treatment methods typically rely on balloon dilation procedures, which often require repeated interventions to maintain airway function.

Airiver Medical’s investigational device combines traditional balloon dilation with targeted drug delivery. The device uses a specialized coating that releases paclitaxel directly into the airway tissue during the procedure, helping prevent the tissue from narrowing again after treatment.

This localized delivery approach is designed to improve treatment durability while limiting exposure to surrounding healthy tissue.

Pivotal Clinical Trial Underway

Airiver Medical has already initiated a U.S. pivotal clinical trial following FDA approval of an investigational device exemption (IDE). The study is expected to enroll up to 200 patients with central airway stenosis and will evaluate the safety and effectiveness of the pulmonary drug-coated balloon compared with standard balloon dilation therapy.

The first patient has already been successfully treated, marking an important step forward in the device’s clinical development.

Addressing a Significant Medical Need

Central airway stenosis remains a difficult condition to manage, with many patients requiring multiple procedures over time to maintain an open airway. In the United States alone, tens of thousands of airway dilation and stenting procedures are performed annually, highlighting the need for more durable treatment options.

If clinical trials demonstrate positive outcomes, Airiver Medical’s pulmonary drug-coated balloon could offer a minimally invasive solution that reduces the need for repeat procedures while improving long-term patient outcomes.

Industry Outlook

Drug-coated balloon technologies have been widely used in cardiovascular treatments, and their application in respiratory medicine represents an emerging area of innovation. Airiver Medical’s approach highlights the growing interest in expanding drug-delivery technologies into new therapeutic fields.

Bottom Line

Airiver Medical’s FDA Breakthrough Device designation represents a significant milestone for the company’s pulmonary drug-coated balloon technology. If the ongoing clinical trial proves successful, the device could introduce a new treatment option for central airway stenosis and help advance innovation in respiratory medical care.